ClinicalTrials.gg
RecruitingNCT04822337Updated Oct 26, 2026

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

A Phase 1/2 interventional study of Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin in Multiple Myeloma, sponsored by Wake Forest University Health Sciences. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Wake Forest University Health Sciences · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Planned enrollment
43rd of 113
70 · median 54
Started
2021
with 4 others
Phase 1/2
28 of 113
3 open now
Primary completion
2029-04
later than 37 of 38 live
Registered
94th of 113
by date
Lead sponsor
3 of 113
Wake Forest University Health Sciences

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 43rd largest by planned enrollment, is one of 5 that started in 2021, is one of 28 in phase 1/2, reaches primary completion later than 37 of the 38 other live ones, and was the 94th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.

Read the detailed description

This is a phase I dose escalation and expansion study in RMM and RRMM followed by a single arm phase II expansion in high risk, NDMM. The phase I portion of the protocol will utilize a standard 3+3 dose escalation design to determine the maximum tolerated dose (MTD) and RP2D of the KRd-belantamab mafodotin combination. The phase II portion of the trial is a two-stage design that will assess the efficacy and safety of the combination in newly diagnosed, high-risk MM patients.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Plasma Cell Neoplasms
  • BCMA
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and HIPAA authorization for release of personal health information signed by the subject or his/her legally authorized representative. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  2. Age greater than or equal to 18 years at the time of consent. Because no dosing or adverse event data are currently available on the use of belantamab mafodotin as a single agent or in combination with KRd in subjects less than 18 years of age, children are excluded from this study.
  3. Performance Status of less than or equal to 2
  4. Demonstrate adequate organ function
  5. Adequate cardiac function as defined by a greater than 40% (LVEF) by ECHO, cardiac MRI or MUGA

    a. Note for subjects in phase II: if a cycle of pre-study induction therapy containing a PI or anthracycline was administered, assessment of the LVEF must be repeated.

  6. For those with symptomatic pulmonary disease with Grade 2 or higher symptoms (e.g. , asthma) or other signs / symptoms of pulmonary disease, adequate pulmonary function as defined by a greater than or equal to 50% of predicted and DLCO/VA greater than or equal to 50% of predicted
  7. Females of (FCBP) must have two negative serum pregnancy tests during screening: the first within 10-14 days prior to first dose of study treatment and the second within 24 hours prior to first dose of study treatment. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), are amenorrhoeic for less than 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the range upon screening evaluation; or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause).
  8. FCBP must be willing to use 2 effective methods (at least one that is highly effective) or abstinence starting from the time of informed consent, while on belantamab mafodotin and lenalidomide. If either drug is discontinued, 2 effective forms of contraception should be continued until at least 4 weeks after the last dose of lenalidomide, and 1 form of effective contraception should be continued until 4 months post last dose of belantamab mafodotin. FCBP should use effective contraception or abstinence from consent until 30 days after last treatment with carfilzomib, and males with a partner of childbearing potential must use effective contraception or abstinence for at least 90 days post last dose of carfilzomib.
  9. Male subjects must agree to the following from the first dose of study treatment until 6 months after the last dose of belantamab mafodotin, to allow for clearance of altered sperm:

    1. Refrain from donating sperm

    PLUS either:

    b. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR c. Must agree to use effective contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner of to use an additional highly effective contraceptive method with a failure rate of less than 1% per year

  10. FCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during the intervention period and for at least 4 months after the last dose of study intervention belantamab mafodotin, at least 30 days after the last dose of carfilzomib, and at least 4 weeks after the last dose of lenalidomide.
  11. As determined by the enrolling physician, ability of the subject to understand and adhere with study procedures for the entire length of the study
  12. Ability to swallow oral medications
  13. Willing to refrain from using contact lenses while participating in this study

INCLUSION CRITERIA - Phase I treatment for or Relapsed/Refractory MM:

  1. Subjects with Relapsed or Relapsed/Refractory MM who have had at least 1 .

    a. Refractory is defined as less than 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment b. A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

  2. Subjects must have , as defined by at least one of the following:

    a. Serum monoclonal protein level greater than or equal to 0.5 g/dL b. 24-hour urinary M-protein greater than or equal to 200 mg c. Involved free light chain level greater than or equal to 10 mg/dL, along with an abnormal free light chain ratio (defined as less than 0.26 or greater than 1.65).

  3. Subject must have not progressed on full dose lenalidomide previously (25 mg on days 1-21 of a 28-day cycle or its dosing equivalent based on renal function at the time of progression)
  4. Prior to enrollment:

    1. There should be a of ≥14 days from any prior chemotherapy AND
    2. The subject must have adequate recovery from toxicity of prior chemotherapy as defined by the following:

    i. Hematologic lab results within parameters noted in Table 3.2.1 ii. Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions:

<!-- -->

  1. Subjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible
  2. Subjects with ≤grade 2 fatigue are eligible
  3. Subjects with ≤grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required
  4. Subjects with ≤grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required
  5. Subjects with ≤grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required
  6. Subjects with less than grade 2 peripheral neuropathy

INCLUSION CRITERIA - Phase II treatment for high-risk newly diagnosed MM:

  1. Active, newly diagnosed multiple myeloma with CRAB features or a myeloma-defining event per the IMWG 2014 criteria. Note: It is acceptable to include subjects who have had one cycle of emergent treatment for multiple myeloma.
  2. High-risk disease at diagnosis, as defined by at least one of the following:

    i. Monoallelic del(1p) along with +1q, or biallelic del(1p) ii. One of those translocations [t(4;14), t(14;16) or t(14;20)]- co-occurring with a +1q and/or del(1p) iii. del(17p)* and/or TP53 mutation iv. High β2M (>5.5 mg/L) with normal creatinine (Note: Both must be performed no more than +/- 7 days apart.) v. Primary plasma cell leukemia: peripheral blood plasma cell percentage >5% as assessed by pathology review of the peripheral smear vi. Presence of extramedullary disease

  3. Measurable disease by 1 or more of the following:

    a. Serum monoclonal protein level greater than or equal to 0.5 g/dL b. 24-hour urinary M-protein greater than or equal to 200 mg c. Involved free light chain level greater than or equal to 10 mg/dL (100 mg/L), along with an abnormal free light chain ratio (defined as less than 0.26 or greater than 1.65).

    d. Note: for subjects who have received a prior cycle of non-protocol therapy, measurable disease will be based on the serum and urine monoclonal protein and serum free light chain levels prior to the cycle of non-protocol therapy

  4. No more than one prior cycle of non-protocol therapy will be allowed, recognizing that high-risk multiple myeloma subjects frequently require immediate therapy at initial diagnosis even before risk assessment is complete. For those subjects who receive a cycle of non-protocol induction therapy:

    1. There should be a washout period of ≥14 days from the last dose of pre-study therapy AND
    2. The subject must have adequate recovery from toxicity of pre-study therapy as defined by the following:

    i. Hematologic lab results within parameters ii. Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions:

<!-- -->

  1. Subjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible
  2. Subjects with less than or equal to grade 2 fatigue are eligible
  3. Subjects with less than or equal to grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required
  4. Subjects with less than or equal to grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required
  5. Subjects with less than or equal to grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required
  6. Subjects with less than grade 2 peripheral neuropathy

Exclusion criteria

EXCLUSION CRITERIA for all subjects:

  1. Active infection requiring systemic therapy. NOTE: at the discretion of the treating investigator, subjects who have started antibiotic therapy for subjects who had symptoms present, symptoms must have improved to baseline or grade 1 in severity may start treatment prior to completion of their course of antibiotic therapy.
  2. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study.)
  3. Subjects cannot have other prior or concomitant except for:

    a. Curatively treated non-melanoma skin cancer b. Other cancer for which the subject has been medically stable for at least 2 years and/or, in the opinion of the Site Principal Investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy

  4. Active central nervous system (CNS) involvement
  5. Concomitant AL amyloidosis or POEMS syndrome
  6. Treatment with any drug within 14 days or five half-lives, whichever is shorter, prior to first dose of study treatment.
  7. Medical, psychiatric, or other condition/disorder (including lab abnormalities) which, in the opinion of the treating physician, would make this protocol treatment unreasonably hazardous for the subject, or could interfere with obtaining or compliance to the study procedures
  8. Significant cardiac disease, including any of the following:

    a. Greater than or equal to Class 3 (NYHA) congestive heart failure (see Appendix B) b. evidence of acute ischemia c. Unstable angina d. Myocardial infarction, Coronary angioplasty, stenting, or bypass grafting within three months prior to day 1 of treatment e. uncontrolled and/or untreated arrhythmias or conduction block, including clinically significant ECG abnormalities such as 2nd degree Mobitz Type ll or 3rd degree atrioventricular (AV)block. However, PACs, PVCs, rate controlled atrial fibrillation, sinus arrhythmia, asymptomatic sinus bradycardia or sinus tachycardia and 1st degree heart block are not considered clinically significant.

    f. Greater than or equal to Grade 2 prolongation (i.e. >480 msec)

  9. Chronic uncontrolled hypertension, defined as a systolic blood pressure of greater than or equal 160 mmHg or a diastolic blood pressure of greater than or equal 90 mmHg based on at least two readings on two or more separate occasions, ideally over 1-4 weeks. Isolated or situational blood pressure elevations may be acceptable at the treating investigator's discretion.
  10. Grade greater than or equal to 2 peripheral neuropathy
  11. Psychiatric illness/social situation that would limit compliance with study requirements as determined by the investigator
  12. Known immediate or delayed or allergic reaction to any components of, or related to, protocol therapy (e.g. during exposure to carfilzomib, lenalidomide or dexamethasone as part of a pre-study cycle of therapy).
  13. History of erythema multiforme to lenalidomide or other IMID
  14. Discontinuation of prior carfilzomib, lenalidomide or dexamethasone due to treatment toxicity
  15. Major surgery within 4 weeks prior to day 1 of treatment
  16. Radiation within 14 days prior to day 1 of treatment. Note: palliative XRT to less than 5% of the total marrow volume as assessed by the treating investigator is allowed within 14 days prior to day 1 of treatment
  17. Current corneal epithelial disease except mild changes in corneal epithelium
  18. Positive antibody test result (this test preferable) or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment

    a. NOTE: Subjects with positive Hepatitis C antibody due to prior eradicated disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained b. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months before first dose of study treatment unless the participant can meet the following criteria: i. RNA test negative ii. Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a of at least 4 weeks.

    NOTE: Hepatitis RNA testing is optional and participants with a negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing

  19. A known diagnosis of
  20. Is seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e. subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Subjects who are PCR positive will be excluded. Subjects with Hepatitis B surface antibodies and previous Hepatitis B vaccination will be eligible.
  21. Has current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria
  22. Participant must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill inclusion criteria
  23. Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment
  24. Any evidence of active mucosal or internal bleeding
  25. Participant must not be simultaneously enrolled in any therapeutic clinical trial
  26. Administration of live or within 30 days prior to the first dose of study treatment a. Exception: Monkeypox vaccine may be given if there are at least 3 days between the vaccine and initiation of study treatment.

28. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drug.

29. Transplant ineligible per institutional guidelines (Phase II)

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Phase I

    Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

    Drug: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

  • Experimental
    Phase II

    Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

    Drug: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

Interventions

06

What researchers measure

Primary outcomes

  1. Establish Maximum Tolerated Dose (MTD)

    DLTs will be determined for each subject enrolled in Phase I as a binary variable indicating whether the subject experienced a DLT during Cycle 1 of belantamab mafodotin-containing protocol directed induction therapy.

    Time frame: time to complete Cycle 1 (28 days)

  2. Evaluate Complete Response (CR)

    CR will be determined for each subject as a binary variable indicating whether the achieved a best overall response to induction therapy of CR or better.

    Time frame: up to 5 years

Secondary outcomes

  1. Complete Response (CR)

    CR will be determined for each subject as a binary variable indicating whether the achieved a best overall response to induction therapy of CR or better

    Time frame: Up to 5 years

  2. Best Response

    The best overall response will be determined as an ordered categorial variable indicating the subject's best response at any point along the treatment continuum.

    Time frame: Up to 5 years

  3. Very Good Partial Response (VGPR)

    will be determined for each subject as a binary variable indicating whether the achieved a best overall response to induction therapy of VGPR or better.

    Time frame: up to 5 year

  4. Overall Response

    The best overall response will be determined as an ordered categorial variable indicating the subject's best response at any point along the treatment continuum

    Time frame: up to 5 years post treatment discontinuation

  5. MRD Negative

    . Minimal residual disease (MRD) (via NGF 10-5 and 10-6) will be determined for each subject after suspected CR for Phase I subjects and at the following timepoints for Phase II subjects: after induction therapy, after ASCT, and after 12 cycles of maintenance therapy (post Cycle 18visit) and every 12 months post Cycle 18 sample.

    Time frame: Up to 5 years

  6. Time to First Response (TTFR)

    TTFR will be calculated for all subjects achieving an sCR, CR, VGPR, or PR. This will be defined as the time from initiation of belantamab mafodotin-containing protocol directed induction therapy to the time of first disease assessment indicating either sCR, CR, VGPR or PR

    Time frame: up to 30 days post treatment discontinuation

  7. Time to Best Response (TTBR)

    Time to best response will be calculated for all subjects achieving an sCR, CR, VGPR or PR. This will be defined as the time from initiation of belantamab mafodotin-containing protocol directed induction therapy to the time of best disease assessment indicating either sCR, CR, VGPR or PR.

    Time frame: up to 30 days post treatment discontinuation

  8. Time to Progression (TTP)

    TTP is defined as the duration of time from enrollment to the study (treatment start date) to first occurrence of progressive disease

    Time frame: Up to 5 years

  9. Duration of Response (DoR)

    DoR will be calculated for each subject achieving a PR or better and will be calculated from the time of the first assessment that identified response until disease progression or death.

    Time frame: Up to 5 years post treatment response

  10. Overall Survival (OS)

    OS is defined as the duration from enrollment to the study (treatment start date) to the date of death from any cause.

    Time frame: Up to 8 years

  11. Progression Free Survival (PFS)

    PFS is defined as the duration of time from enrollment to the study (treatment start date) to first occurrence of either progressive disease or death (from any cause), whichever comes first.

    Time frame: Up to 8 years

Other outcomes

  1. Safety - Serious Adverse Events (SAEs)

    The SAE variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined SAE.

    Time frame: Up to 4-8 weeks post treatment discontinuation

  2. Safety - Adverse Events (AEs)

    The AE variable will be determined for each subject as a binary variability indicating whether or not subject experienced an AE per CTCAE V5.0.

    Time frame: Up to 4-8 weeks post treatment discontinuation

  3. Safety - Adverse Events of Special Interest (AESIs)

    The AESI variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined AESI.

    Time frame: Up to 4-8 weeks post treatment discontinuation

  4. Translational Research - PFS and OS

    Describe subject outcomes of progression free survival and overall survival for MRD concordant and discordant cases

    Time frame: Up to 8 years

  5. Translational Research - MRD Status

    Compare MRD status concordance between NGF and QiP mass spectrometry

    Time frame: Up to 8 years

  6. Translational Research - BCMA expression

    Assess BCMA (B Cell Maturation Antigen) expression by plasma cells prior to therapy and at relapse using formalin-fixed paraffin embedded (FFPE) bone marrow biopsies.

    Time frame: Up to 8 years

  7. Translational Research - Immunologic Profiles

    Establish peripheral blood and bone marrow immunologic profiles throughout therapy.

    Time frame: Up to 8 years

  8. Translational Research - plasma BCMA expression

    Correlate plasma cell BCMA (B Cell Maturation Antigen) expression with Progression Free Survival (PFS) and Overall Survival (OS).

    Time frame: Up to 8 years

  9. Translational Research - serum BCMA concentration

    Correlate serum cell sBCMA (serum B Cell Maturation Antigen) concentration with Progression Free Survival (PFS) and Overall Survival (OS).

    Time frame: Up to 8 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Atrash S, Symanowski J, Robinson M, Flynn C, Norek S, Cox R, Plott M, Bumgarner K, Rhinehardt D, Begic X, Ndiaye A, Robinson J, Friend R, Paul B, Varga C, Ferreri C, Pineda-Roman M, Foureau D, Bhutani M, Voorhees P. Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma. Blood Adv. 2026 May 12;10(9):2925-2936. doi: 10.1182/bloodadvances.2025019050. PubMed 41719502 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Apr 2029, 95 months after the start.

Of 103 non-industry phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 95 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Mar 30, 2021
StartActual
May 19, 2021
Primary completionEst.
Apr 2029
CompletionEst.
Nov 2032
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 26, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Levine Cancer Institute · Charlotte, United Statesno status→Recruiting
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United Statesno status→Recruiting
Oct 26, 2026
Eligibility
7 inclusion criteria edited, 11 added, 7 removed; 4 exclusion criteria edited, 3 added, 8 removed
What changed in the criteria
Inclusion criteria
  • RemovedBe abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
  • RemovedMust agree to use effective contraception/barrier as detailed below:
  • EditedBe abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR c. Must agree to use effective contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner of reproductive potential to use an additional highly effective contraceptive method with a failure rate of less than 1% per year
  • RemovedRefractory is defined as less than 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment
  • RemovedA line of therapy is defined as one or more cycles of a planned treatment program.
  • EditedRefractory is defined as less than 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment b. A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.
  • RemovedSerum monoclonal protein level greater than or equal to 0.5 g/dL
  • Removed24-hour urinary M-protein greater than or equal to 200 mg
  • EditedSerum monoclonal protein level greater than or equal to 0.5 g/dL b. 24-hour urinary M-protein greater than or equal to 200 mg c. Involved free light chain level greater than or equal to 10 mg/dL, along with an abnormal free light chain ratio (defined as less than 0.26 or greater than 1.65).
  • AddedThere should be a washout period of ≥14 days from any prior chemotherapy AND
  • AddedThe subject must have adequate recovery from toxicity of prior chemotherapy as defined by the following:
  • EditedThere should be a washout period of ≥14 days from any prior chemotherapy AND b. The subject must have adequate recovery from toxicity of prior chemotherapy as defined by the following: i. Hematologic lab results within parameters noted in Table 3.2.1 ii. Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions:
  • EditedHigh-risk disease at diagnosis, as defined by at least one of the following:
  • ChangedBefore Del(1p) ii. Gain of 1q21 [greater than or equal to 3 copies] iii. Monosomy 13 or del(13q) by conventional karyotype iv. High risk IgH translocation [t(4;14), t(14;16) or t(14;20)] v. del(17p)Now Monoallelic del(1p) along with +1q, or biallelic del(1p) ii. One of those translocations [t(4;14), t(14;16) or t(14;20)]- co-occurring with a +1q and/or del(1p) iii. del(17p)* and/or TP53 mutation iv. High β2M (>5.5 mg/L) with normal creatinine (Note: Both must be performed no more than +/- 7 days apart.) v. Primary plasma cell leukemia: peripheral blood plasma cell percentage >5% as assessed by pathology review of the peripheral smear vi. Presence of extramedullary disease
  • AddedThere should be a washout period of ≥14 days from the last dose of pre-study therapy AND
  • AddedThe subject must have adequate recovery from toxicity of pre-study therapy as defined by the following:
  • EditedThere should be a washout period of ≥14 days from the last dose of pre-study therapy AND b. The subject must have adequate recovery from toxicity of pre-study therapy as defined by the following: i. Hematologic lab results within parameters ii. Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions:
  • Removed1. Subjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible 2. Subjects with less than or equal to grade 2 fatigue are eligible 3. Subjects with less than or equal to grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required 4. Subjects with less than or equal to grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required 5. Subjects with less than or equal to grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required 6. Subjects with less than grade 2 peripheral neuropathy
  • Added<!-- -->
  • AddedSubjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible
  • AddedSubjects with less than or equal to grade 2 fatigue are eligible
  • AddedSubjects with less than or equal to grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required
  • AddedSubjects with less than or equal to grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required
  • AddedSubjects with less than or equal to grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required
  • AddedSubjects with less than grade 2 peripheral neuropathy
Exclusion criteria
  • RemovedCuratively treated non-melanoma skin cancer
  • EditedCuratively treated non-melanoma skin cancer b. Other cancer for which the subject has been medically stable for at least 2 years and/or, in the opinion of the Site Principal Investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy
  • RemovedPlasma cell leukemia
  • RemovedGreater than or equal to Class 3 New York Heart Association (NYHA) congestive heart failure (see Appendix B)
  • RemovedECG evidence of acute ischemia
  • RemovedUnstable angina
  • RemovedMyocardial infarction, Coronary angioplasty, stenting, or bypass grafting within three months prior to day 1 of treatment
  • EditedGreater than or equal to Class 3 New York Heart Association (NYHA) congestive heart failure (see Appendix B) b. ECG evidence of acute ischemia c. Unstable angina d. Myocardial infarction, Coronary angioplasty, stenting, or bypass grafting within three months prior to day 1 of treatment e. Clinically significant uncontrolled and/or untreated arrhythmias or conduction block, including clinically significant ECG abnormalities such as 2nd degree Mobitz Type ll or 3rd degree atrioventricular (AV)block. However, PACs, PVCs, rate controlled atrial fibrillation, sinus arrhythmia, asymptomatic sinus bradycardia or sinus tachycardia and 1st degree heart block are not considered clinically significant.
  • EditedUncontrolledChronic uncontrolled hypertension, defined as a systolic blood pressure of greater than or equal to 160 mmHg or a diastolic blood pressure of greater than or equal to 90 mmHg based on at least two readings on two or more separate occasions, ideally over 1-4 weeks. Isolated or situational blood pressure elevations may be acceptable at the treating investigator's discretion.
  • RemovedNOTE: Subjects with positive Hepatitis C antibody due to prior eradicated disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained
  • AddedNOTE: Subjects with positive Hepatitis C antibody due to prior eradicated disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained b. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months before first dose of study treatment unless the participant can meet the following criteria: i. RNA test negative ii. Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period of at least 4 weeks.
  • AddedNOTE: Hepatitis RNA testing is optional and participants with a negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing
  • RemovedAdministration of live or live-attenuated vaccines within 30 days prior to the first dose of study treatment
  • EditedAdministration of live or live-attenuated vaccines within 30 days prior to the first dose of study treatment a. Exception: Monkeypox vaccine may be given if there are at least 3 days between the vaccine and initiation of study treatment.
  • Added29. Transplant ineligible per institutional guidelines (Phase II)
Oct 26, 2026
Contact
Study contact now listed: added k•••@atriumhealth.org · •••2520; added S•••@atriumhealth.org · •••9322. See the current contact
Oct 26, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Levine Cancer Institute · Charlotte, United StatesContact added S•••@advocatehealth.org · •••2341
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United StatesContact added J•••@wfusm.edu · •••5440Contact added (no phone or email listed)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Active, not recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Levine Cancer Institute · Charlotte, United Statesno status→Recruiting
    • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United Statesno status→Recruiting
    Eligibility 7 inclusion criteria edited, 11 added, 7 removed; 4 exclusion criteria edited, 3 added, 8 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedBe abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
    • RemovedMust agree to use effective contraception/barrier as detailed below:
    • EditedBe abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR c. Must agree to use effective contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner of reproductive potential to use an additional highly effective contraceptive method with a failure rate of less than 1% per year
    • RemovedRefractory is defined as less than 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment
    • RemovedA line of therapy is defined as one or more cycles of a planned treatment program.
    • EditedRefractory is defined as less than 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment b. A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.
    • RemovedSerum monoclonal protein level greater than or equal to 0.5 g/dL
    • Removed24-hour urinary M-protein greater than or equal to 200 mg
    • EditedSerum monoclonal protein level greater than or equal to 0.5 g/dL b. 24-hour urinary M-protein greater than or equal to 200 mg c. Involved free light chain level greater than or equal to 10 mg/dL, along with an abnormal free light chain ratio (defined as less than 0.26 or greater than 1.65).
    • AddedThere should be a washout period of ≥14 days from any prior chemotherapy AND
    • AddedThe subject must have adequate recovery from toxicity of prior chemotherapy as defined by the following:
    • EditedThere should be a washout period of ≥14 days from any prior chemotherapy AND b. The subject must have adequate recovery from toxicity of prior chemotherapy as defined by the following: i. Hematologic lab results within parameters noted in Table 3.2.1 ii. Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions:
    • EditedHigh-risk disease at diagnosis, as defined by at least one of the following:
    • ChangedBefore Del(1p) ii. Gain of 1q21 [greater than or equal to 3 copies] iii. Monosomy 13 or del(13q) by conventional karyotype iv. High risk IgH translocation [t(4;14), t(14;16) or t(14;20)] v. del(17p)Now Monoallelic del(1p) along with +1q, or biallelic del(1p) ii. One of those translocations [t(4;14), t(14;16) or t(14;20)]- co-occurring with a +1q and/or del(1p) iii. del(17p)* and/or TP53 mutation iv. High β2M (>5.5 mg/L) with normal creatinine (Note: Both must be performed no more than +/- 7 days apart.) v. Primary plasma cell leukemia: peripheral blood plasma cell percentage >5% as assessed by pathology review of the peripheral smear vi. Presence of extramedullary disease
    • AddedThere should be a washout period of ≥14 days from the last dose of pre-study therapy AND
    • AddedThe subject must have adequate recovery from toxicity of pre-study therapy as defined by the following:
    • EditedThere should be a washout period of ≥14 days from the last dose of pre-study therapy AND b. The subject must have adequate recovery from toxicity of pre-study therapy as defined by the following: i. Hematologic lab results within parameters ii. Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions:
    • Removed1. Subjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible 2. Subjects with less than or equal to grade 2 fatigue are eligible 3. Subjects with less than or equal to grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required 4. Subjects with less than or equal to grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required 5. Subjects with less than or equal to grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required 6. Subjects with less than grade 2 peripheral neuropathy
    • Added<!-- -->
    • AddedSubjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible
    • AddedSubjects with less than or equal to grade 2 fatigue are eligible
    • AddedSubjects with less than or equal to grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required
    • AddedSubjects with less than or equal to grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required
    • AddedSubjects with less than or equal to grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required
    • AddedSubjects with less than grade 2 peripheral neuropathy
    Exclusion criteria
    • RemovedCuratively treated non-melanoma skin cancer
    • EditedCuratively treated non-melanoma skin cancer b. Other cancer for which the subject has been medically stable for at least 2 years and/or, in the opinion of the Site Principal Investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy
    • RemovedPlasma cell leukemia
    • RemovedGreater than or equal to Class 3 New York Heart Association (NYHA) congestive heart failure (see Appendix B)
    • RemovedECG evidence of acute ischemia
    • RemovedUnstable angina
    • RemovedMyocardial infarction, Coronary angioplasty, stenting, or bypass grafting within three months prior to day 1 of treatment
    • EditedGreater than or equal to Class 3 New York Heart Association (NYHA) congestive heart failure (see Appendix B) b. ECG evidence of acute ischemia c. Unstable angina d. Myocardial infarction, Coronary angioplasty, stenting, or bypass grafting within three months prior to day 1 of treatment e. Clinically significant uncontrolled and/or untreated arrhythmias or conduction block, including clinically significant ECG abnormalities such as 2nd degree Mobitz Type ll or 3rd degree atrioventricular (AV)block. However, PACs, PVCs, rate controlled atrial fibrillation, sinus arrhythmia, asymptomatic sinus bradycardia or sinus tachycardia and 1st degree heart block are not considered clinically significant.
    • EditedUncontrolledChronic uncontrolled hypertension, defined as a systolic blood pressure of greater than or equal to 160 mmHg or a diastolic blood pressure of greater than or equal to 90 mmHg based on at least two readings on two or more separate occasions, ideally over 1-4 weeks. Isolated or situational blood pressure elevations may be acceptable at the treating investigator's discretion.
    • RemovedNOTE: Subjects with positive Hepatitis C antibody due to prior eradicated disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained
    • AddedNOTE: Subjects with positive Hepatitis C antibody due to prior eradicated disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained b. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months before first dose of study treatment unless the participant can meet the following criteria: i. RNA test negative ii. Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period of at least 4 weeks.
    • AddedNOTE: Hepatitis RNA testing is optional and participants with a negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing
    • RemovedAdministration of live or live-attenuated vaccines within 30 days prior to the first dose of study treatment
    • EditedAdministration of live or live-attenuated vaccines within 30 days prior to the first dose of study treatment a. Exception: Monkeypox vaccine may be given if there are at least 3 days between the vaccine and initiation of study treatment.
    • Added29. Transplant ineligible per institutional guidelines (Phase II)
    Contact Study contact now listed: added k•••@atriumhealth.org · •••2520; added S•••@atriumhealth.org · •••9322. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Levine Cancer Institute · Charlotte, United StatesContact added S•••@advocatehealth.org · •••2341
    • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United StatesContact added J•••@wfusm.edu · •••5440Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04822337
Collaborators
Amgen, GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 30, 2021
Start date
May 19, 2021
Primary completion
Apr 2029 (estimated)
Completion
Nov 2032 (estimated)
Last update
Oct 26, 2026

Study contacts

Kelly Bumgarner, RN
Contact
kelly.bumgarner@atriumhealth.org
704-403-2520
Shebli Atrash, MD, MS
Contact
Shebli.Atrash@atriumhealth.org
704-774-9322
Shebli Atrash, MD, MS
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Lenalidomide · Dexamethasone · Belantamab mafodotin

Start the discussion